High-dose chemotherapy (HDC) followed by autologous stem cell rescue (ASCR) is the only curative treatment for metastatic retinoblastoma, but its feasibility in developing countries is unknown. We report 11 consecutive children (six unilateral) treated in three South-American middleincome countries with HDC-ASCR. One patient had metastatic retinoblastoma at diagnosis and the remaining ones had a metastatic relapse. Metastatic sites included BM ¼ 6, bone ¼ 4, orbit ¼ 5 and central nervous system (CNS) ¼ 4. All patients received induction with conventional chemotherapy achieving CR at a median of 5.7 months from the diagnosis of metastasis. Conditioning regimens included carboplatin and etoposide with thiotepa in six or with CY in four or melphalan in one patient. All patients engrafted after G-CSF-mobilized peripheral blood ASCR and no toxic deaths occurred. Two children received post-ASCR CNS radiotherapy. Seven children have disease-free survival (median follow-up 39 months). CNS relapse, isolated (n ¼ 3) or with systemic relapse (n ¼ 1), occurring at a median of 7 months after ASCT was the most common event. In the same period, five children with metastatic retinoblastoma did not qualify for HDC-ASCR and died. We conclude that HDC-ASCR is a feasible and effective treatment for children with metastatic retinoblastoma in middle-income countries.
Introduction
Retinoblastoma is the most frequent primary neoplasm of the eye in childhood. More than 95% of affected children in industrialized countries survive, 1 and the most likely explanation for these excellent results is early diagnosis, which is determined by adequate access to health care and early consultation with specialists that lead to the detection of the disease well before it disseminates outside the eye. Metastatic retinoblastoma at presentation is, therefore, uncommon in the most developed countries, but it is still the major cause of mortality of retinoblastoma in less developed countries. 2 However, in middle-income countries like most South-American nations, metastatic retinoblastoma became less common in recent years, 2 because of earlier diagnosis, but it is still a problem in some less developed countries of our region.
Survival of metastatic retinoblastoma was traditionally poor, until the advent of high-dose chemotherapy (HDC) regimens followed by autologous stem cell rescue (ASCR). [3] [4] [5] [6] Results from the most recent Latin-American series reporting patients treated with conventional chemo-and radiotherapy regimens were discouraging with survival figures from 0 to 20%. 3, 7, 8 Only occasional patients with distant metastatic disease survived and the few survivors reported with conventional chemotherapy included those who had metastasis limited to the lymph nodes, 9 which are now considered as regionally disseminated rather than a distant metastatic site. 10 High-dose chemotherapy followed by ASCR was not available in our setting until recently and, to our knowledge, there are no reported results of this treatment modality for retinoblastoma from less developed countries. Because of its high cost and limited availability, results of ASCR for the treatment of this tumor are of interest in order to assign priorities for this modality in our setting.
Therefore, the aim of this study was to report the feasibility and survival results of a series of patients with metastatic retinoblastoma treated with HDC and ASCR at centers in Argentina, Uruguay and Chile, in which BMT units have been recently created, and access to this treatment is granted by the public health care system.
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Subjects and methods
Setting
This report includes all consecutive patients with metastatic retinoblastoma transplanted at three referral centers in Argentina, Chile and Uruguay. The Hospital Calvo Mackenna and the Hospital Pereyra Rosell are the only public institutions in Chile and Uruguay, respectively, that offer SCT and their retinoblastoma program is also located at those institutions, hence, the population from those centers is representative of their national situation. More than 80% of Argentine patients with retinoblastoma are treated at the Hospital JP Garrahan in Buenos Aires. However, ASCT was not available at that hospital until 2008. Therefore, patients treated there were referred to affiliated institutions for the procedure. Nevertheless, the entire treatment plan was agreed with those institutions, and patients were given initial treatment and post transplant follow-up at the Hospital JP Garrahan. These two pediatric transplant units also received patients from other pediatric oncology centers in Argentina (Table 1, patients 5 and 7 ) and, as they were treated with the same guidelines, they are included in this report.
Patients
Treatment with HDC and ASCR for metastatic retinoblastoma, detected at diagnosis or at relapse, was offered systematically for patients diagnosed after 2002 in our setting. Children with trilateral retinoblastoma were not included in this analysis.
Between January 2002 and December 2008, 11 (7 male, 4 female) patients with metastatic retinoblastoma were transplanted. The International Staging System for Retinoblastoma was used for staging at diagnosis. Characteristics of the patients are summarized in Table 1 . Median age at diagnosis of retinoblastoma was 28.4 (range 8-70) months. Six patients had unilateral retinoblastoma and five had bilateral disease.
Only one patient had metastatic retinoblastoma at diagnosis (stage 4a, bilateral disease) and the remaining ones developed metastatic disease during follow-up.
Given the low patient number, only descriptive data are provided. This treatment followed the Declaration of Helsinki principles and was approved by the local institutional research ethics committee, when applicable. The parents or legal guardians of all patients provided written informed consent for the treatment. Survival status was updated to July 2010.
Definitions
Granulocytic engraftment was defined as the first day of ANCs greater than 0.5 Â 10 9 /L for three consecutive days and platelet engraftment was defined as the first day of selfsustained platelet count greater than 50 Â 10 9 /L, with no platelet transfusions for at least 7 days.
Results
Pre-transplant treatment
Treatment for intraocular disease. At the time of disease diagnosis, six patients (five with unilateral disease) underwent enucleation. The patient with bilateral disease was treated with initial enucleation of one eye and chemoreduction and local therapy for the fellow eye. Metastatic disease developed at a median of 7.4 months after enucleation (range 4-10). Two of these patients had tumor invasion to the retrolaminar optic nerve, with resection margin free of tumor and two had focal choroidal invasion. Two had no pathology risk factor. No adjuvant therapy was given to any patient, according to the local treatment protocols. 8, 12 In four children (three with bilateral disease), metastatic disease developed after an initial conservative approach with chemoreduction was attempted. They had received a median of six cycles of chemoreduction with carboplatin, etoposide and vincristine, and all received external beam radiotherapy for conservative treatment. However, enucleation of affected eyes was necessary in three cases with bilateral disease. In one of these patients, post-laminar optic nerve invasion was found on pathology examination. Metastatic disease developed between 34 and 83 months from diagnosis. In the case in which metastatic disease developed after 83 months from diagnosis, the patient's family refused enucleation of their child's remaining single eye. That girl had an orbital progression followed by central nervous system (CNS) invasion, after seeking treatment elsewhere and came back to the Hospital JP Garrahan for treatment of relapse. The contralateral eye had been enucleated upfront at diagnosis and had no pathology risk factors.
Clinical description of metastatic sites. Seven patients had metastatic disease outside the CNS, including the BM in four, the orbit in three and multiple bones in two. No patient had isolated orbital involvement. Four patients had CNS involvement at the time of developing metastatic disease. In all cases it occurred with other metastatic sites such as the orbit in three, the BM in two and multiple bones in one. CNS involvement included positive CSF cytology in two and CNS (pre-chiasmatic mass) mass in the remaining two.
Pre-transplant treatment of metastatic disease. As patients were treated in different institutions, there were no common guidelines; however, they received treatment with conventional chemotherapy with fairly similar regimens, including previously reported regimens, with alternating etoposide-carboplatin and vincristine, idarubicin and CY in five children, included in the Hospital JP Garrahan protocol. 8, 12 The remaining children received this combination with topotecan in one, or ifosfamide with carboplatin and a topoisomerase inhibitor and doxorubicin in four or cisplatin, etoposide, CY and vincristine as per the COG-ARET 0321 regimen in one case.
Stem cell transplantation. All patients underwent autologous hematopoietic stem cell collected from the peripheral blood after G-CSF mobilization, at a median of 5.7 months (range 2.7-14.1 months) from diagnosis of metastatic disease. Ten patients underwent one leukapheresis procedure and the remaining patient underwent two procedures in order to obtain a sufficient number of CD34 þ cells (median: 6 Â 10 6 cells/kg; range: 4.9-8.1 Â 10 6 cells/kg). In one patient (#6), there was a 2-month delay caused by insurance denial. All patients were transplanted in CR of metastatic retinoblastoma (10 in first CR and 1 in second CR). Six patients received a thiotepa-containing preparative regimen, including high-dose carboplatin, thiotepa and etoposide as reported by Dunkel et al. 5 as a preparative regimen. However, thiotepa was not available in Argentina during some periods of this study, therefore, four patients received high-dose carboplatin, etoposide and CY as reported by Namouni et al. 6 and one patient received high-dose carboplatin, melphalan and etoposide. 13 All patients had a successful engraftment. The median day of granulocytic engraftment was day þ 10 (range: day 10-11) and the median day for platelet engraftment was day þ 36 (range . No non-hematological grade IV toxicity occurred and no patient died of toxicity. The median hospitalization time was 23 days (range: 19-29 days).
Post transplant treatment. There were no common guidelines for post transplant therapy and this was decided individually by each center. Three patients (with CNS metastasis) received post-ASCR craniospinal radiation therapy and one patient received conservative eye irradiation, whereas the remaining ones did not receive any form of post transplant radiation therapy (Table 1) . Interestingly, none of the five children that survived after HDT-ASCR for metastatic disease outside the CNS received radiotherapy to the metastatic sites, including the orbit in three and bone in five.
Survival. Seven patients have an EFS at a median of 39 months (range 27-56) of follow-up. Four patients had a metastatic relapse of retinoblastoma at a median of 7 months (range 2-36) after transplant and all died soon thereafter of retinoblastoma progression. Five of seven and two of four patients, without and with CNS involvement, respectively, became long-term survivors. Four of the six that received a thiotepa-based preparative regimen survived compared with three of five of those receiving other regimens. Four of five children that had received chemoreduction therapy before HDC-ASCR became long-term survivors compared with three of six of those that were not exposed to chemotherapy before the occurrence of metastatic disease.
The site of the post transplant metastatic relapse included the CNS in all cases (leptomeningeal dissemina- tion alone in three and combined with multiple bone metastasis in one). Patients received palliative care after this event. No child had a secondary malignancy.
Discussion
To our knowledge, this is the first report of a series of children surviving metastatic retinoblastoma after treatment with HDC and ASCR in middle-income countries. The effectiveness of this treatment was already reported by different groups from the United States and Europe, but only single cases from developing countries were reported previously as part of other international publications.
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Most single-institution reports included single cases or small series with less than five patients in most instances. 5, 14, [16] [17] [18] [19] [20] To our knowledge, only two reports included more than 10 patients and they concluded that consolidation with HDC and ASCR provides a chance for cure, estimated to be in the range of 60-70%, especially for children with metastatic disease outside the CNS. 6, 15 Despite the fact the results in children with CNS dissemination were poorer, recent reports showed that some children with CNS invasion 14 or with trilateral disease 21 could be cured with this strategy. Treatment with conventional chemotherapy and radiotherapy is not effective for the treatment of metastatic retinoblastoma, hence, only anecdotal survivors were reported from midincome countries.
3,4,9 Therefore, our results provide supportive evidence that HDC followed by ASCR is the best treatment option for children with metastatic retinoblastoma, also in our setting.
The occurrence of metastatic disease at diagnosis in retinoblastoma appears to be influenced critically by delays in the diagnosis, which are, in turn, related to poor sociocultural conditions. 2 In addition, in less developed countries, many families of children with intraocular retinoblastoma opt out of recommended treatment, therefore, leading to subsequent metastatic dissemination and death, 2, 22 as happened with one of our cases. All these factors explain why metastatic retinoblastoma is more common in less developed countries. Though encouraging, our results should not be interpreted as the solution for the problem of metastatic retinoblastoma in developing countries. Only timely diagnosis and better communication with affected families, in order to improve treatment compliance, will improve the outcome of children with retinoblastoma worldwide. 2 However, ASCR is currently available in many middle-income countries and children with metastatic retinoblastoma may be good candidates for this procedure, as our results show that this modality would be at least as effective as it is for other tumors in which it is considered a standard procedure, such as neuroblastoma. 23, 24 Beds for ASCR, when available, are usually scarce in middle-income countries, therefore, children with highly curable diseases are given higher priority. 25 Because of the low number of cases with metastatic retinoblastoma reported in the literature, in the absence of results replicating the international experience, this disease usually receives a relatively low priority in transplant units from developing countries in which children with metastatic retinoblastoma are more common. However, our results show that these results can be replicated in our setting, with comparable or even better results than those of other solid tumors, such as neuroblastoma, in which o40% of children survive after this treatment. 23 Therefore, extending this treatment in order to include a higher number of cases and identify prognostic factors and the optimal treatment regimen is a priority for this tumor.
There are still unanswered questions about the treatment of children with metastatic retinoblastoma with HDC and ASCR. These include: the proposed superiority of thiotepacontaining regimens and the use of post transplant radiotherapy to involved bulky sites that could not be addressed by this study and the previous reports. 5, 6, [16] [17] [18] 20, 26 The current international multi-center trial (COG ARET 0321) will be a key instrument for responding these questions. 27 Metastatic retinoblastoma is now less frequent in South America, 28 probably because of earlier diagnosis. Compliance to recommended treatment is high in these countries. 2 Consequently, only 11 cases with metastatic retinoblastoma, most of them at relapse were seen in our referral centers in this 6-year period. In that period, an estimated 300 patients were treated in our institutions, but there were patients with metastatic retinoblastoma that could not receive HDC-ASCR. For example, in the study interval, despite there being no cases with metastatic retinoblastoma that were not included in this study from Uruguay, there were three children at the Hospital JP Garrahan and at least two in Chile that had metastatic disease, either at diagnosis or at relapse and did not achieve a CR with conventional chemotherapy or were treated palliatively and failed to qualify for HDC-ASCR. Therefore, the OS results when patients that do not qualify for HDC-ASCR are considered are lower.
It is interesting to note that our series contained a relatively high proportion of children that developed metastatic retinoblastoma after failed attempts for conservative therapy, who may have been cured with timely enucleation. This event has been published previously from less developed and developed countries. [29] [30] [31] [32] Timely enucleation of relapsed-resistant intraocular retinoblastoma is mandatory to prevent the occurrence of metastatic dissemination. As reported previously by Dunkel et al., 15 children that presented metastatic relapse after failing chemoreduction are still salvageable with intensive chemotherapy and ASCR, but their chances may be lower than for chemotherapy-naı¨ve patients. In our series, two out of four patients that relapsed after failing chemoreduction had CNS compromise at relapse and only one survived. Overall, CNS relapse occurred in two out of four children that had received chemotherapy for treatment of intraocular disease compared with two of seven of those who were chemotherapy naı¨ve. Therefore, previous chemotherapy exposure might result in higher rates of CNS involvement, 8 leading to poorer survival. Our results cannot provide conclusions about the potential superiority of thiotepa-containing regimens Four out of six children that received thiotepacontaining regimens survive (including two out of three surviving children with CNS involvement), whereas three out of five children who received other regimens (including none out of one surviving children with CNS involvement), thereby when thiotepa is not available, patients may still be salvageable with this modality. The use of post transplant radiotherapy is a matter of debate. Radiotherapy may increase the risk of secondary malignancies in children with germline mutations of the Rb1 gene, and cranial or craniospinal radiation are known to cause severe neurodevelopmental problems in young children. Both our longterm survivors with CNS invasion received craniospinal radiotherapy as further consolidation. There are reports of children with CNS metastasis and trilateral disease who achieve a sustained CR with HDC and stem cell rescue, without craniospinal radiotherapy, 19, 21 therefore, its use is under discussion. The use of radiotherapy in cases of metastatic disease outside the CNS is also controversial. Interestingly, none of our patients received radiotherapy to extra-CNS sites and they still did well.
To conclude, our results confirmed an estimated 60-70% of survival of children with metastatic retinoblastoma treated with HDC and ASCR in our setting, and provide preliminary data for the feasibility and safety for the replication of results obtained in higher-resource settings in middle-income countries.
